EndocrinologyTRANSNCT07163832
Retrospective Study of the Cohort of Transgender Patients Who Began Medical Support Before the Age of 18
An observational study of Endocrinology, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Gender incongruence is characterized by a marked and persistent incongruity between the gender with which a person identifies and their assigned sex. Behaviors and preferences that vary by sex do not, in and of themselves, justify the assignment of diagnoses in this group. Read more about this study
- Who is it for?
- Ages 8 to 17 years
- Conditions the study is for
- Endocrinology
- How many people
- 115 participants
- Where
- 1 siteFrance
- Study dates
- 15 May 2025to 15 May 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Minor patient (≥18 years old) who has been consulted for the first time for transgender issues at the Strasbourg University Hospital in child psychiatry and/or pediatric endocrinology (in at least one of the two departments)
Who may be able to join
- Minor patient (≥18 years old)
- First-time patient for transgender issues at the Strasbourg University Hospital in child psychiatry and/or pediatric endocrinology (in at least one of the two departments)
- Patient (and/or their legal representative) who has not expressed opposition to the reuse of their data for scientific research purposes.
Who cannot join
- Patient (and/or their representative) who has expressed opposition to the reuse of their data for scientific research purposes.
- Patient aged over 18 at the first consultation
- Patient with insufficient data
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de pédiatrie 1 - CHU de Strasbourg - France
Strasbourg, 67091
François BREZIN, MD, 03.88.12.77.34, francois.brezin@chru-strasbourg.fr
François BREZIN, MD
About this study
Official title: Retrospective Single-center Study of the Cohort of Transgender Patients Who Began Medical Support Before the Age of 18 at the Strasbourg University Hospital
Gender incongruence is characterized by a marked and persistent incongruity between the gender with which a person identifies and their assigned sex. Behaviors and preferences that vary by sex do not, in and of themselves, justify the assignment of diagnoses in this group.
- Conditions
- Endocrinology
- Keywords
- Pediatric endocrinology, Child Psychiatry
What is being measured
The primary outcome is the main question the study is designed to answer.
Retrospective descriptive study of the population of transgender minors receiving medical support at the Strasbourg University Hospital
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2025
- Study start15 May 2025
- Primary completionMay 2026 (estimated)
- Study completion15 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndocrinologyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 115 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07163832
- Sponsor's protocol ID
- 9688
- Acronym
- TRANS
- Status last verified
- Sep 2025
- First submitted
- 1 Sep 2025
- Last updated
- 9 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No